ESMO Open最新文献

{"title":"64P Molecularly unselected immune-based versus non-immune-based trials: Outcomes in refractory metastatic castrate resistant prostate cancer (mCPRC) at Sarah Cannon Research Institute (SCRI) UK","authors":"K. Chandran , H. Almarzouq , Y.F. Zheng , B. Kelly , L. Kenehan , A. Williams , R. Grochot , R. Amofa , E. Fontana","doi":"10.1016/j.esmoop.2026.106205","DOIUrl":"10.1016/j.esmoop.2026.106205","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106205"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria","authors":"N. Dobrić ,&nbsp;S.O. Hasenleithner ,&nbsp;C. Suppan ,&nbsp;E.V. Klocker ,&nbsp;D. Hlauschek ,&nbsp;R. Graf ,&nbsp;C. Beichler ,&nbsp;C. Albertini ,&nbsp;D. Egle ,&nbsp;D. Liu ,&nbsp;A.M. Starzer ,&nbsp;R. Bartsch ,&nbsp;T. Moser ,&nbsp;G. Rinnerthaler ,&nbsp;P.J. Jost ,&nbsp;E. Heitzer ,&nbsp;N. Dandachi ,&nbsp;M. Balic","doi":"10.1016/j.esmoop.2026.106939","DOIUrl":"10.1016/j.esmoop.2026.106939","url":null,"abstract":"<div><h3>Background</h3><div>Advances in endocrine therapies for hormone receptor (HR)-positive/HER2-negative advanced breast cancer (ABC) continue to transform care and significantly improve patient outcomes. However, the integration of molecular and clinical risk stratification into guiding individualized treatment selection remains a key challenge. We therefore evaluated whether the integration of baseline circulating tumor DNA (ctDNA)-derived tumor metrics enhances risk stratification among patients receiving early lines of treatment of HR-positive ABC in a real-world multicenter cohort of patients in Austria.</div></div><div><h3>Methods</h3><div>Patients with HR-positive/HER2-negative ABC treated at multiple Austrian centers were included. CtDNA was analyzed using a 77-gene panel (AVENIO ctDNA Expanded Kit). Tumor fraction (TFx) was estimated via two complementary approaches: untargeted aneuploidy assessment using mFAST-SeqS, and the highest variant allele frequency (hVAF) from the AVENIO assay. Somatic variants and single, binary, and three-level composite TFx metrics were assessed for their association with progression-free and overall survival (PFS, OS).</div></div><div><h3>Results</h3><div>We analyzed 225 ctDNA samples from 184 patients [128 before first-line (1L) and 76 before second-line (2L) treatment], including 40 paired samples. Overall TFx was low (median z-score 2.49; range −0.5-208.3), with higher levels in 2L, although the difference did not reach statistical significance (<em>P</em> = 0.058). In contrast, the hVAF was significantly higher in the 2L cohort (<em>P</em> = 0.007). Somatic variant burden was significantly increased in 2L (<em>P</em> &lt; 0.001), with notably more frequent <em>ESR1</em> mutations (26.7% versus 7.1% in 1L). Median PFS was 29.2 months in 1L and 6.0 months in 2L, while median OS was 57.3 months and 16.1 months, respectively. <em>TP53</em> and <em>ESR1</em> mutations, and all ctDNA-based metrics were significantly associated with PFS and OS, with a three-level composite ctDNA variable showing the highest prognostic discrimination.</div></div><div><h3>Conclusions</h3><div>Our findings demonstrate that integrating baseline ctDNA-derived TFx metrics with established clinical variables significantly improves risk stratification in HR-positive/HER2-negative ABC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106939"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"54P ALOX5-driven lipid metabolism underlies therapy resistance via enhanced DNA repair","authors":"M. Li","doi":"10.1016/j.esmoop.2026.106160","DOIUrl":"10.1016/j.esmoop.2026.106160","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106160"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"120eP Exploring the balance between mitogenic activation and inhibition of cellular stress pathways in tumorigenic and non-tumorigenic cells","authors":"K.A.M. Torres,&nbsp;R. Wailemann,&nbsp;T.E.P. Torres,&nbsp;F. Montoni,&nbsp;H. Armelin","doi":"10.1016/j.esmoop.2026.106261","DOIUrl":"10.1016/j.esmoop.2026.106261","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106261"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"92MO Efficacy of vorasidenib in patients with IDH-mutant gliomas previously treated with ivosidenib","authors":"S. Schultz ,&nbsp;J. Barreto ,&nbsp;J. Uhm ,&nbsp;B. Neth ,&nbsp;M. Wren Ruff ,&nbsp;J.L. Campian ,&nbsp;U. Sener","doi":"10.1016/j.esmoop.2026.106234","DOIUrl":"10.1016/j.esmoop.2026.106234","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106234"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"15P DLL3-directed T cell redirection as a therapeutic strategy for medullary thyroid cancer","authors":"S. Suzuki ,&nbsp;N. Choudhury ,&nbsp;E. Tolosa ,&nbsp;J. Ayers-Ringler ,&nbsp;K.E. Smith ,&nbsp;L. Yang ,&nbsp;F. Kosari ,&nbsp;A.S. Mansfield","doi":"10.1016/j.esmoop.2026.106118","DOIUrl":"10.1016/j.esmoop.2026.106118","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106118"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation","authors":"Z. Ianniello,&nbsp;E. Quijano,&nbsp;D.A. Colón-Ríos,&nbsp;M. Rackear,&nbsp;P.M. Glazer","doi":"10.1016/j.esmoop.2026.106115","DOIUrl":"10.1016/j.esmoop.2026.106115","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106115"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"32P Whole-slide histopathology embeddings enable non-genomic HER2 biomarker prediction in esophageal adenocarcinoma","authors":"K. Nijjer ,&nbsp;A. Ahmed","doi":"10.1016/j.esmoop.2026.106136","DOIUrl":"10.1016/j.esmoop.2026.106136","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106136"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"98P Optimizing treatment for CDK4/6 inhibitor-resistant breast cancer using patient-derived models","authors":"B. Policastro ,&nbsp;N. Nissen ,&nbsp;M.K. Jakobsen ,&nbsp;S. Ehmsen ,&nbsp;O.L. Gammelgaard ,&nbsp;F. Rosengren ,&nbsp;L.E. Johansen ,&nbsp;J. Staaf ,&nbsp;H.J. Ditzel ,&nbsp;C.L. Alves","doi":"10.1016/j.esmoop.2026.106240","DOIUrl":"10.1016/j.esmoop.2026.106240","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106240"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"111P EGFR and MET mRNA overexpression in non-small cell lung cancer: Prevalence and sensitivity to targeted therapies","authors":"S. Garcia-Roman ,&nbsp;C. Aguado ,&nbsp;E. Marin ,&nbsp;C. Mayo de Las Casas ,&nbsp;M. Garzón-Ibáñez ,&nbsp;N. Jordana Ariza ,&nbsp;R. Roman ,&nbsp;E. Aldeguer ,&nbsp;S. Muñoz ,&nbsp;I. Sánchez ,&nbsp;R. Reyes ,&nbsp;M.F. García Casabal ,&nbsp;R. Rosell ,&nbsp;M.A. Molina-Vila","doi":"10.1016/j.esmoop.2026.106253","DOIUrl":"10.1016/j.esmoop.2026.106253","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106253"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}